CERS Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of -4.96% compared to Cerus's net margin of -18.58%. Cerus's return on equity of -39.46% beat Retractable Technologies's return on equity of -16.83%.

Cerus has a consensus price target of $4.25, signalling upside risk potential of 248.36%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Cerus has higher upside potential than Retractable Technologies, analysts believe Cerus is more attractive than Retractable Technologies.

Cerus has a beta of 1.701, which suggesting that the stock is 70.134% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Cerus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cerus pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Cerus quarterly revenues are $50.8M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Cerus's net income of -$2.5M is lower than Retractable Technologies's net income of -$1.9M. Notably, Cerus's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cerus is 1.25x versus 0.63x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -4.96% compared to Cerus's net margin of -1226.82%. Cerus's return on equity of -39.46% beat VolitionRX's return on equity of --.

Cerus has a consensus price target of $4.25, signalling upside risk potential of 248.36%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 535.65%. Given that VolitionRX has higher upside potential than Cerus, analysts believe VolitionRX is more attractive than Cerus.

Cerus has a beta of 1.701, which suggesting that the stock is 70.134% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

Cerus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cerus pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Cerus quarterly revenues are $50.8M, which are larger than VolitionRX quarterly revenues of $474.5K. Cerus's net income of -$2.5M is higher than VolitionRX's net income of -$5.8M. Notably, Cerus's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cerus is 1.25x versus 32.27x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -4.96% compared to Cerus's net margin of -4291.67%. Cerus's return on equity of -39.46% beat Catheter Precision's return on equity of -65.84%.

Cerus has a consensus price target of $4.25, signalling upside risk potential of 248.36%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 566.67%. Given that Catheter Precision has higher upside potential than Cerus, analysts believe Catheter Precision is more attractive than Cerus.

Cerus has a beta of 1.701, which suggesting that the stock is 70.134% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.775, suggesting its less volatile than the S&P 500 by 177.508%.

Cerus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cerus pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Cerus quarterly revenues are $50.8M, which are larger than Catheter Precision quarterly revenues of $96K. Cerus's net income of -$2.5M is higher than Catheter Precision's net income of -$4.1M. Notably, Cerus's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cerus is 1.25x versus 2.06x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -4.96% compared to Cerus's net margin of -10.04%. Cerus's return on equity of -39.46% beat Xtant Medical Holdings's return on equity of -35.34%.

Cerus has a consensus price target of $4.25, signalling upside risk potential of 248.36%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 358.96%. Given that Xtant Medical Holdings has higher upside potential than Cerus, analysts believe Xtant Medical Holdings is more attractive than Cerus.

Cerus has a beta of 1.701, which suggesting that the stock is 70.134% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

Cerus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cerus pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Cerus quarterly revenues are $50.8M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. Cerus's net income of -$2.5M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Cerus's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cerus is 1.25x versus 0.43x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.